Synaptogenix Inc (SNPX)

[Inoviorulez]

That's how the biotech game goes. Although the good news in biotech is once it happens once to you, you know how to spot these little things. For instance, I had high hopes for CNAT with its NASH drug emricasan. They pulled a phase 2 study with no placebo and listed ad hoc analysis and data mined results. Needless to say it failed all 3 studies.

In the end, it's all about learning initial studies whether or not they are done with a placebo and not data mined as you describe. NO position in this, but I'm sorry for the loss of those who lost big in this. Chalk this up as a learning lesson and just be aware of the little stuff like p-values, no placebo, data mining results. I hope NTRP shareholders recover though.